Cefuroxime axetil in the treatment of cutaneous infections.

Abstract

A multicenter clinical trial was conducted in 125 out-patients with skin and skin structure infections due to bacteria in order to compare the safety and efficacy of cefuroxime axetil and cefaclor. Patients with a median age of 32 years were randomly allocated to treatment for 10 days with one of three treatments: cefuroxime axetil 250 mg b.i.d., cefuroxime axetil 500 mg b.i.d., or cefaclor 250 mg t.i.d. Clinical evaluations of each patient were done pre-treatment, 2 to 4 days intra-treatment, and within 3 days post-treatment. One patient discontinued cefuroxime axetil due to severe urticaria and one patient discontinued cefaclor due to a persistent headache and vomiting. Cefuroxime axetil was an effective antibacterial agent for treatment of common skin infections. Clinically beneficial outcome was achieved for 92% (cefuroxime axetil 250 mg b.i.d.), 95% (cefuroxime axetil 500 mg b.i.d.), and 97% (cefaclor 250 mg t.i.d.) of patients. Since the study failed to demonstrate a significant advantage of higher dosage, cefuroxime axetil should be prescribed in a regimen of 250 mg twice a day for patients with skin infections.

• Authors: L C Parish, D M Cocchetto, K Werner, D L Jungkind, J Witkowski
• Journal: International journal of dermatology (Int J Dermatol) 1987 Jul-Aug Vol. 26 Issue 6 Pg. 389-93 ISSN: 0011-9059 [Print] England
• PMID: 3305394 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Cephalosporins
• Cefaclor
• Cefuroxime
• Cephalexin
• cefuroxime axetil

Topics

• Adolescent
• Adult
• Aged
• Cefaclor (adverse effects, therapeutic use)
• Cefuroxime (adverse effects, analogs & derivatives, therapeutic use)
• Cephalexin (analogs & derivatives)
• Cephalosporins
• Child
• Clinical Trials as Topic
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Random Allocation
• Skin Diseases, Infectious (drug therapy, microbiology)